HSK40118

Haisco Pharmaceutical Group Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	HSK40118
Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation (PHASE1)
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation (PHASE1)
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HSK40118 CI brief — competitive landscape report
HSK40118 updates RSS · CI watch RSS
Haisco Pharmaceutical Group Co., Ltd. portfolio CI